Trulieve Cannabis Corp. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2026. Trulieve Cannabis Corp. is a vertically integrated multi-state cannabis operator with 236 dispensaries and 15 cultivation/processing facilities across nine U.S. states. The company operates under a regional hub structure (Southeast, Northeast, Southwest) and is the largest cannabis retailer in the United States. A significant regulatory development occurred on April 23, 2026, when the U.S. Department of Justice finalized the rescheduling of medical marijuana from Schedule I to Schedule III, impacting federal tax and regulatory restrictions for medical operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $286.8 million | $297.8 million |
| Gross Profit | $170.1 million | $183.2 million |
| Gross Margin | 59.3% | 61.5% |
| Net Income (Loss) | $2.3 million | ($33.8 million) |
| Adjusted EBITDA | $100.4 million | $109.2 million |
| Operating Cash Flow | $55.7 million | $51.1 million |
| Cash and Equivalents | $352.9 million | $329.4 million |
| Total Debt (Notes Payable + Private Placement) | $285.7 million | $227.6 million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 4% year-over-year to $286.8 million. This was driven by a $16.8 million drop in retail revenue due to price compression, partially offset by a $5.8 million increase in wholesale revenue.
- Profitability Turnaround: The company reported a net income of $2.3 million, a significant improvement from a net loss of $33.8 million in Q1 2025. This shift was primarily due to a $30.6 million reduction in the provision for income taxes, as the company did not apply IRC Section 280E for the 2026 taxable year.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 12% to $104.9 million, largely due to a reduction in campaign and political contributions ($9.5 million vs. $23.0 million in the prior year).
- Debt Increase: Total debt obligations increased due to the issuance of $60 million in new private placement notes (Tranche Two) in Q1 2026, bringing total private placement notes to $200 million.
Outlook, Risks, and Contingencies
- Regulatory Outlook: Following the DOJ rescheduling of medical cannabis to Schedule III, Trulieve has applied for DEA licenses in Florida, Georgia, Pennsylvania, and West Virginia. Adult-use operations remain illegal under federal law until rescheduling is finalized.
- Tax Contingencies: The company maintains a significant uncertain tax position liability of $696.4 million, primarily related to IRC Section 280E challenges. The IRS proposed penalties of approximately $38.1 million in September 2025, which the company intends to contest vigorously.
- Liquidity: Management believes existing cash balances of $352.9 million are sufficient to meet requirements for the next 12 months. Future capital needs may be met through operations, debt, or equity financings.
- Operational Risks: Risks include federal illegality of adult-use cannabis, potential civil asset forfeiture, RICO liability, and intense market competition.
Investor Verification Checklist
- Tax Position Viability: Verify the status of the IRS audit and the likelihood of the company successfully defending its position against IRC Section 280E and the proposed $38.1 million penalty.
- DEA Licensing: Monitor the approval status of DEA licenses for medical-only states following the Schedule III rescheduling.
- Debt Covenants: Confirm continued compliance with financial covenants on the $200 million private placement notes and other long-term borrowings.
- Price Compression: Assess the sustainability of retail revenue given the noted price compression trends in core markets.
- Discontinued Operations: Review the ongoing impact of discontinued operations (Massachusetts and Nevada exits) on cash flow and asset reclassifications.